GlassScriptPhysician profile
Padma Devi Ramiah
NPI 1366931750
$4,202.13
in general payments reported to CMS, 2019-2025
20 companies · $858 in 2025
The $858 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $652 · 2023: $906 · 2024: $1,489 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.14 | 2021-2025 | |
| Lilly USA, LLC | $679.68 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $448.81 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $367.77 | 2024-2025 | Repatha, Evenity |
| Pfizer INC. | $263.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.95 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $218.37 | 2024 | Eliquis, Zeposia |
| Esperion Therapeutics, INC. | $216.61 | 2021-2024 | Nexlizet, Nexletol |
| Astrazeneca Pharmaceuticals LP | $210.17 | 2023-2025 | Lokelma, Farxiga, Airsupra |
| Boston Scientific Corporation | $133.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2024 | Austedo Xr |
| Madrigal Pharmaceuticals | $122.84 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $110.74 | 2025 | |
| Inspire Medical Systems, INC. | $106.64 | 2023 | Inspire |
| Aimmune Therapeutics, INC. | $81.32 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.80 | 2024-2025 | Cologuard Collection Kit |
| Kci USA, INC. | $32.99 | 2023 | Activ.A.C. |
| Glaxosmithkline, LLC. | $25.45 | 2025 | Shingrix, Arexvy |
| Acadia Pharmaceuticals INC | $21.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Ramiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.